Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEA for Chronic Inflammatory Pain
NCT06273462Phase 2Recruiting
- Sponsor
- Naval Medical Center San Diego
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic inflammatory pain comparing Palmitoylethanolamide with Placebo (2 arms). Primary endpoint: Pain Level at 8 weeks. Started Aug 2024; status: recruiting.
02
Drugs
palmitoylethanolamide
03
Conditions
chronic inflammatory pain
Beyond the preview
Go deeper on NCT06273462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06273462.